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Background: We have developed a new diagnostic method using the photosensitizer 5-aminolevulinic acid (5ALA)
for diagnosing intrathoracic malignant lesions. When ingested exogenously, 5ALA is metabolized to a heme precursor,
protoporphyrin IX, which stays in malignant cells and emits red to pink luminescence of about 630 nm.
Methods: We enrolled 40 patients who underwent respiratory surgery and consented to participate in this study.
Twenty-eight patients had primary lung cancer, 8 metastatic lung tumors, 2 malignant pleural tumors, and 2 benign
tumors. Localization of malignant lesions was attempted by observing such lesions with an autofluorescence imaging
system and by comparing the color tone of the autofluorescence between malignant lesions and normal tissues after
oral administration of 5ALA. Malignant lesions on the pleural surface emitted pink autofluorescence in contrast to the
green autofluorescence of the surrounding normal tissues.
Results: When 28 patients with primary lung cancer were examined according to the degree of pleural infiltration (pl),
red fluorescence was confirmed in 10 of 10 patients (100%) with p11-p13 and 5 of 18 patients (27.7%) with p10. The latter
5 patients had been diagnosed with PL1 preoperatively or intraoperatively.
Conclusion: This system achieved accurate localization of malignant lesions, suggesting that it may also be applicable to
photodynamic therapy.
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Diagnostic imaging techniques such as computed tomog-
raphy, magnetic resonance imaging, and positron emission
tomography (PET), as well as visual diagnosis during sur-
gery, are of limited value for diagnosing early malignant
pleural mesothelioma or minute intrathoracic dissemin-
ation that may contribute to intrathoracic recurrence after
surgery for lung cancer. Thus, a highly accurate method of
evaluation and diagnosis is awaited. Focusing attention on
autofluorescence, we endeavored to develop a new method
of photodynamic diagnosis (PDD) using an autofluores-
cence imaging system. However, the initial system had
drawbacks such as limitations in the visualization of lesions
and unclear borders between normal tissues and malignant
lesions [1]. We thus made efforts to improve the accuracy* Correspondence: k1111@asahikawa-med.ac.jp
Department of Respiratory Center, Asahikawa Medical University,
Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan
© 2015 Kitada et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.of this system. Five-aminolevulinic acid (5ALA), a photo-
sensitizer, thereby came to our attention. Exogenous 5ALA
is ingested and then metabolized to the heme precursor
protoporphyrin IX, which stays in malignant cells and
shows photogenesis, emitting red to pink fluorescence of
about 630 nm [2]. At present, this issue is studied in the
fields of neurosurgery involving brain tumors [3] and ur-
ology involving bladder and prostate cancers [4,5], but there
are no reports describing the use of this technique for intra-
thoracic malignant lesions. In this study, we gave 5ALA
orally to lung cancer patients prior to surgery, and then
viewed malignant lesions using the autofluorescence im-
aging system. By comparing the color tone of autofluores-
cence between normal tissues and malignant lesions, we
were able to devise a highly accurate method of localizing
malignant lesions.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The principle of autofluorescence observation. Normal tissue: In response to blue excitation rays of approximately 400–450 nm,
green autofluorescence of approximately 520 nm is observed. Malignant Lesion: Autofluorescence is reduced due to thickening of the mucosal
epithelium, decrease in autofluorescent substances, an increase in fluorescence absorbing substances, etc., causing the color spectrum of emitted
fluorescence to shift.
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Autofluorescence imaging system
Autofluorescence is spontaneous emission of fluores-
cence that occurs when biological structures such as
mitochondria and lysosomes absorb light. The sources
of autofluorescence in human tissues are collagen and fi-
bronectin, in addition to nicotinamide-adenine dinucleo-
tide phosphate and flavin-adenine dinucleotide [6,7]. In
normal tissues, green autofluorescence of about 520 nm
can be observed in response to blue excitation rays of
400–450 nm. In contrast, in cancer lesions, green auto-
fluorescence is reduced, or the color tone of the emittedFigure 2 The autofluorescence observation system. A small CCD came
to enable white light and autofluorescence to be observed via a filter. The
Olympus endoscopic system attachment.fluorescence is changed, due to thickening of the muco-
sal epithelium, a decrease in autofluorescent substances,
or an increase in fluorescence-absorbing substances
(Figure 1). The autofluorescence observation system
allows autofluorescence to be observed by visualizing de-
creases or changes in the wavelengths of the fluores-
cence, and this system has already been applied clinically
in the field of bronchoscopy. In this study, we endeavored
to establish a method for the diagnosis of intrathoracic ma-
lignant lesions using a thoracoscope (rigid scope) equipped
with the autofluorescence imaging system. The autofluores-
cence imaging system used in this study was shown to bera is attached to the endoscopic color fluorescence system PDS-2000,
color fluorescence camera is equipped with a thoracoscope using the
Figure 3 The metabolic pathway of 5ALA. Exogenous 5ALA is ingested and promptly metabolized to heme in normal cells. In contrast, the
fluorescent substance protoporphyrin IX accumulates selectively in cancer cells, emitting red to pink fluorescence of about 630 nm, because
cancer cells have high porphobilinogen deaminase activity and low ferrochelatase activity.
Table 2 Patients baseline characteristics and pathology of
primary lung cancer (n=28)
baseline characteristics and pathology
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(Hamamatsu Photonics, Shizuoka, Japan) equipped with a
small charge-coupled device (CCD) camera, allowing the
observation of white light and autofluorescence via a
filter [8,9]. A thoracoscope was attached to the color
fluorescence camera, using an Olympus endoscopic
system attachment. In addition, the LED light source,
which can emit an excitation wavelength of light with
a peak at 420 nm, was used (Figure 2).
5ALA
5ALA is the starting material in the 5-porphiline syn-
thetic pathway, and is a natural amino acid in the human
body. It is an endogenous amino acid synthesized from
glycine and succinyl CoA in mitochondria, and is also a
precursor of hemoglobin. When exogenous 5ALA is
ingested, it is promptly metabolized to heme in normal
cells. In contrast, in cancer cells, where the activity of
porphobilinogen deaminase is high and the activity of
ferrochelatase is low, the fluorescent substance protopor-
phyrin IX accumulates selectively. Consequently, red to
pink fluorescence of about 630 nm is emitted (Figure 3).
ALA does not stagnate at the infection part of the lung.
The subjects were patients who underwent respiratory
surgery during the period between July 2013 and April
2014 and consented to participate in this study. OurTable 1 PL category: pleural invasion of lung cancer
PL category
PL0 Tumor within the subpleural parenchyma, or, invading
superficially into the pleural connective tissue below
the elastic layer.
PL1 Tumor invades beyond the elastic layer.
PL2 Tumor invades to visceral pleural surface.
PL3 Tumor invades the parietal pleura.system was used for a total of 40 cases: 28 cases with
primary lung cancer, 8 with metastatic lung tumors,
Renal cell carcinoma:1 Prostata carcinoma:1 Breast can-
cer:1, Colorectal carcinoma:3, Uterus cancer:1, Adenoid
cystic ca of the trachea:1), 2 with malignant pleural tu-
mors, and 2 with benign tumors (leiomyoma, nerve
sheath tumors). We performed lobectomy or segmen-
tectomy for lung cancer, partial lung resection for meta-
static lung cancer, biopsies for malignant pleural tumors,
and tumor resection for benign tumors. According to
the degree of pleural infiltration of pathological findings
(pl), the lung cancers were p10 in 18 cases, p11 in 3, p12
in 3, and p13 in 4. Exogenous 5ALA at 20 mg/kg was
given orally to patients 3–4 hours before the beginning
of surgery. Intrathoracic conditions were observed im-
mediately after the initiation of surgery, employing a
thoracoscope equipped with the autofluorescence observa-
tion system inserted through a 12-mm port. PL category
was determined by diagnostic imaging before surgery, and
pl category was determined by pathological examination
after surgery. PL category is shown to the Table 1. This
study was approved by the Ethics Committee of theMean age 69.1(46–79)
Gender Men: Women: 15:13
Pathology Adenocarcinoma :21 , Squamous cell carcinoma 5
Large cell carcinoma: 1; Pleomorphic carcinoma: 1
pT factor T1a/T1b/T2a/T2b/T3/T4: 12/5/4/4/1/2
PL factor PL0/PL1/PL2/PL3: 13/8/3/4
pl factor pl0/pl1/pl2/pl3: 18/3/3/4
p-stage I/II/III/IV:19/6/2/1
Figure 4 Lung cancer (a pl1 case). The tumor emits red light, whereas normal tissue shows green autofluorescence, providing clear borders
demarcating the tumor from surrounding tissues.
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tained from each patient prior to surgery.
Table 2 displays a summary of patient baseline charac-
teristics. In the lung cancer patients, it showed a disease
staging and pathological finding.
Results
There were no adverse events attributable to oral admin-
istration of 5ALA.
Visualization
Lesions not distinguishable with white light could be
visualized employing the autofluorescence camera; the
well-defined tumor site was visualized as a pink mass in
contrast to the green autofluorescence emitted by the
surrounding normal tissues. Clearly demarcated lung
cancer with p12 pleural invasion is shown in Figure 4.
Pleural malignant mesothelioma with red to pink autofluo-
rescence is shown in Figure 5. Metastatic lung tumors were
also visualized similarly in all patients (Figure 6). Another
disseminated lesion detected employing this system is
shown in Figure 7. In this patient undergoing surgery based
on the preoperative diagnosis of T2N0, the area of pleural
dissemination was seen as red fluorescence, whereas there
was no change in the color of the thickened part of the
fibrous pleura.Figure 5 Malignant Pleural Mesothelioma. Red light is seen on the pariVisualization of red fluorescence
1. All metastatic lung tumors present on the pleural
surface were visualized even when they were
very small. Two pleural malignant mesotheliomas
were also successfully visualized. Benign tumors
(leiomyoma of the trachea and neurinoma of the
mediastinum) were also observed at the time of
surgery, and there were no changes in color tone in
any of these cases.
2. Red fluorescence was confirmed in 15 of 28 patients
(53.5%) with primary lung cancer. In terms of the
degree of pleural invasion, the tumor was visualized
in 10/10 (100%) cases with p11-p13. Although
visualization was confirmed in 5/18 (27.7%) p10
cases, all 5 cases had been diagnosed as suspected
PL1 (the degree of pleural infiltration of gross
appearance or image diagnosis preoperatively).
Thus, we were able to localize the lesions when
there was suspected or definitive contact or
infiltration of the tumor lesions into the pleura.
Discussion
A possible causative factor in the early recurrence of
lung cancer is the presence of minute disseminated
lesions. Accurate diagnosis of such lesions is a veryetal pleural surface, consistent with the tumor.
Figure 6 Metastatic pulmonary tumor from renal cell carcinoma. The tumor, although very small, emits red light, whereas normal tissue
shows green autofluorescence.
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egies. Considerable attention has been given to early
diagnosis of malignant pleural mesothelioma, which has
a poor prognosis and has as yet no established standard
treatment. It is true that there are limitations in visual
diagnosis with preoperative diagnostic imaging or thora-
coscopic visualization, and a diagnostic method with
high accuracy is therefore desired. We have been carry-
ing out studies focused on autofluorescence of normal
tissues emitted in response to an excitation wavelength
of light. We have also been striving to improve our diag-
nostic system, by correcting its drawbacks such as un-
favorable visualization of lesions and unclear borders
between normal tissues and malignant lesions [1].
Although studies on PDD using 5ALA have been re-
ported for brain tumors, and so on, in the field of neuro-
surgery [3], and for bladder and prostate cancers in the
field of urology [4,5], there are no reports describing
such a study for thoracic malignant lesions. We haveFigure 7 Lung Cancer (a pleural dissemination case). Disseminated lesi
of a clinical T2N0 lesion. Red light is present in the area of pleural disse
pleural thickening.assessed PDD based on the observation of green intrin-
sic fluorescence emitted by normal tissue and changes in
tone due to decreased fluorescent substances in malig-
nant tumor tissue, employing our own observation
system. The results showed that this system allowed us
to depict actual lesions. However, because the lesion
borders were blurred in some cases, the accuracy of our
system required improvement. We consider the current
study to demonstrate that PDD combined with 5ALA
administration allows more accurate diagnosis of malig-
nant lesions exposed on the pleural surface and that our
system is effective for the detection and localization of
small disseminated lesions and small metastatic tumors
in lung cancer.
This technique yielded favorable results for lesions ex-
posed on the pleura but had limitations in terms of lo-
calizing lesions without pleural invasion (pl0). In cases
pathologically diagnosed as pl1 to pl3, localization was
achieved with certainty. In pl0 cases, although someons were detected during surgery under the preoperative diagnosis
mination, whereas no color change is seen in the area of fibrous
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be depicted, depiction of PL0 lesions was difficult. The
pleural invasion (pl) factor is emphasized in lung cancer
tissue classification, and the differentiation between pl0
and pl1 lesions has important implications for lung can-
cer treatment guidelines and for therapeutic strategies
including surgical procedures [10]. Taking these points
into consideration, we have found our technique to be
effective. Differentiation between benign and malignant
lesions is also an important issue. In this study, there
were distinct differences between malignant and benign
lesions including fibrous thickening and neurogenic tu-
mors, suggesting that our technique is applicable, to
some extent, to differential diagnosis, i.e., distinguishing
malignant from benign lesions. However, high standard-
ized uptake values on PET have been reported in cases
with inflammatory masses such as those of IgG4-related
disease [11], underscoring the importance of further in-
vestigations in this area.
Although this study addressed the diagnosis of intra-
thoracic malignant disease, using 5ALA, we believe that
the application of this technique is necessary not only to
diagnosis but also to photodynamic therapy (PDT). In
combination with heat therapy, the inhibitory effect of
PDT on tumor growth was reported to be markedly en-
hanced by accumulation of protoporphyrin IX in tumor
tissue after administration of 5ALA [12] and PDT with
5ALA achieved decreases in epidermal growth factor re-
ceptor expression and the degree of infiltration of cancer
cells [13]. At present, two oncotropic photosensitizers,
i.e., Photofrin (porfimer sodium) [14] and Laserphyrin
(talaporfin sodium) [15], are approved for use in PDT.
The principle of PDT is as follows: the photosensitizer is
activated by laser light to produce active oxygen in the
cellular recovery phase, resulting in attacks on malignant
cells. To date, laser irradiation covering a wide area has
been used to treat the malignant tumor site because
oncotropic photosensitizers characteristically accumulate
in malignant tumors rather than in normal tissues. How-
ever, selective localization using 5ALA may allow more
selective laser irradiation, improving its therapeutic ef-
fect. This technique may also be useful as a new treat-
ment for malignant pleural mesothelioma for which no
current consensus on effective therapy exists. Studies of
this issue are also underway.
Conclusion
Photodynamic diagnosis using 5ALA for malignant in-
trathoracic lesions was carried out. In comparison with
diagnosis using the autofluorescence observation system
alone, it was possible to localize lesions based on the
difference in color tone. In the future, localization of
malignant intrathoracic lesions using 5ALA may allow
PDT of high accuracy.Consent
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